Survodutide

Mechanism

A next-generation dual-action injection that activates both GLP-1 and glucagon receptors. The glucagon component adds extra fat-burning on top of the appetite suppression from GLP-1. In trials, it's shown impressive weight loss (~19%) and significant liver fat reduction for fatty liver disease (MASH).

Effects

## Metabolic System [Tier 1 - Phase II/III Human Data] - Dual agonism of GLP-1 receptor (appetite suppression, insulin sensitization) AND glucagon receptor (hepatic fat oxidation, thermogenesis, energy expenditure) - Phase II trials demonstrated up to 18-19% body weight loss at 46 weeks, exceeding most single-agonist GLP-1 therapies - Glucagon receptor activation increases resting energy expenditure by 50-100 kcal/day through hepatic thermogenesis and futile cycling - Significant reductions in hepatic steatosis (fatty liver) — glucagon receptor activation directly promotes hepatic lipid oxidation - MASH/NASH trials show histological improvement in liver fibrosis and inflammation scores ## Gastrointestinal System [Tier 1 - Human Data] - GLP-1 component delays gastric emptying, reducing post-prandial glucose excursions - Nausea, vomiting, and diarrhea are the most common adverse effects (GLP-1 class effect), typically dose-dependent and transient - Lower GI side effect burden than some pure GLP-1 agonists at equivalent weight loss, possibly due to partial glucagon-mediated offset ## Cardiovascular System [Tier 2 - Secondary Endpoints] - Reductions in total cholesterol, LDL, and triglycerides observed in Phase II - Improvements in blood pressure consistent with weight loss magnitude - Glucagon receptor activation may have direct cardiac effects — glucagon is used acutely for beta-blocker overdose (positive inotrope/chronotrope) - Long-term cardiovascular outcomes trials not yet completed ## Hepatic System [Tier 1 - Primary Endpoint in MASH Trials] - Glucagon receptor agonism is uniquely hepatotropic — promotes fatty acid oxidation, ketogenesis, and amino acid catabolism in hepatocytes - Phase II MASH data showed 47-62% of patients achieved MASH resolution without worsening fibrosis - Liver fat reduction measured by MRI-PDFF exceeded 50% relative reduction in responders - May become first-in-class treatment for metabolic liver disease ## Endocrine System [Tier 1 - Human Data] - Glucagon component raises blood glucose acutely, but GLP-1 component's insulin-sensitizing effects predominate chronically - Net effect is improved glycemic control in most patients, though less HbA1c reduction than pure GLP-1 agonists - Does not significantly affect thyroid function, cortisol, or sex hormones in available data ## Musculoskeletal System [Tier 2 - Secondary Analysis] - Lean mass preservation appears better than semaglutide at equivalent weight loss, possibly due to glucagon-mediated protein turnover signaling - No direct muscle anabolic effects, but glucagon-stimulated amino acid metabolism may preserve muscle protein synthesis rates

Practitioner Guide

## Clinical Positioning Survodutide occupies a unique niche: it is the leading dual GLP-1/glucagon agonist with the strongest MASH/fatty liver data of any incretin-class therapy. For patients whose primary concern is fatty liver disease WITH weight loss, survodutide may be the optimal choice over semaglutide or tirzepatide. ## Current Availability (as of early 2026) - Phase III trials ongoing (Boehringer Ingelheim) - NOT yet FDA-approved - NOT available through compounding pharmacies (proprietary molecule) - Patients asking about survodutide are typically following clinical trial news — redirect to available alternatives while monitoring approval timeline ## Dosing (From Clinical Trials) - Titration schedule: 0.3mg → 0.6mg → 1.2mg → 2.4mg → 4.8mg → 6.0mg weekly SC injections - Each dose step held for 4 weeks before escalation - Maximum studied dose: 6.0mg weekly - Administered subcutaneously in abdomen, thigh, or upper arm ## Patient Selection Best candidates: - MASH/NAFLD with elevated ALT and hepatic steatosis on imaging - Patients who lost weight on semaglutide but liver enzymes remain elevated - Metabolic syndrome with visceral/hepatic fat predominance - Patients who want weight loss WITH metabolic liver disease treatment Less ideal candidates: - Type 1 diabetes (glucagon component could worsen glycemic volatility) - History of medullary thyroid carcinoma or MEN2 (GLP-1 class boxed warning) - Patients with very low BMI or sarcopenia (glucagon increases catabolism) ## Side Effect Management - Nausea: slow titration, take with small meals initially, ginger/ondansetron PRN - Hypoglycemia risk: lower than pure GLP-1 due to glucagon component, but monitor if on sulfonylureas or insulin - Transient hyperglycemia: may occur early in titration before GLP-1 effects predominate — reassure patients ## Comparison to Alternatives - vs. Semaglutide: survodutide has stronger liver fat reduction; semaglutide has more cardiovascular outcomes data and is available now - vs. Tirzepatide: different dual mechanism (GLP-1/GIP vs. GLP-1/glucagon); tirzepatide is better for pure weight loss magnitude; survodutide is better for liver disease - vs. Retatrutide: retatrutide is a triple agonist (GLP-1/GIP/glucagon) that may combine the best of both, but has less mature clinical data

Dosing Protocols

Contraindications & Cautions

• hard stop — History of pancreatitis
  GLP-1 component carries pancreatitis risk consistent with the GLP-1 agonist class. Patients with history of pancreatitis are at elevated risk of recurrence.
  Action: Do not use. Refer to physician for alternative therapies.
• hard stop — Medullary thyroid carcinoma or MEN2 syndrome
  GLP-1 receptor agonists cause thyroid C-cell tumors in rodents. Patients with personal or family history of MTC or MEN2 are at unacceptable risk.
  Action: Do not use. Refer to oncologist/endocrinologist.
• hard stop — Pregnancy
  Dual GLP-1/glucagon agonist poses potential embryo-fetal toxicity risk. No adequate human data. Investigational compound.
  Action: Discontinue immediately if pregnancy is detected. Do not initiate during pregnancy.
• hard stop — Breastfeeding
  Insufficient data. Investigational compound. Do not use during lactation.
  Action: Do not use while breastfeeding.
• hard stop — Gastroparesis
  GLP-1 component delays gastric emptying. Contraindicated with pre-existing gastroparesis.
  Action: Do not use in patients with diagnosed gastroparesis.
• hard stop — Under 18 years of age
  Investigational compound. Not for pediatric use.
  Action: Do not provide to individuals under 18.
• hard stop — Other GLP-1 receptor agonists
  Concurrent use of multiple GLP-1-containing agonists causes dangerous additive effects.
  Action: Never combine multiple GLP-1 agonists. Ensure adequate washout before switching.
• requires physician — Insulin
  Complex glucose dynamics from dual GLP-1/glucagon agonism with exogenous insulin. Risk of both hypoglycemia and hyperglycemia depending on dosing dynamics.
  Action: Requires physician supervision. Frequent blood glucose monitoring mandatory.
• requires physician — History of eating disorders
  Significant appetite suppression and weight loss may trigger eating disorder relapse.
  Action: Requires physician evaluation and mental health screening.

Evidence

• Emerging pharmacotherapies for obesity: A systematic review

  Kokkorakis M, Chakhtoura M, Rhayem C, Al Rifai J, Ghezzawi M, Valenzuela-Vallejo L, Mantzoros CS (2025) — Pharmacol Rev — PMID: 39952695

  Incretin-based phase 2 trials show 7.4-24.2% mean weight loss. 14 ongoing phase 3 trials for next-generation agents. Retatrutide (GLP-1/GIP/glucagon triple agonist) and CagriSema (GLP-1/amylin) show greatest promise with potential for bariatric-surgery-level weight loss. Survodutide (GLP-1/glucagon RA) and orforglipron (oral GLP-1 RA) in phase 3. Oral semaglutide 50mg first oral agent to complete phase 3.

  strong

• A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis

  Sanyal AJ, Bedossa P, Engeli S, Frias JP, Haegele-Link S, Hockings PD, Kliers I, Manuilova E, Palmer C, Pawlak M, Rist S, Tilman V, Treccani C, Trefts E, Hartman ML (2024) — New England Journal of Medicine — PMID: 38587239

  Survodutide (a GLP-1/glucagon receptor dual agonist) achieved MASH resolution without worsening fibrosis in up to 83% of patients at the highest dose (6 mg) vs 18.2% with placebo at 48 weeks. Significant improvements in fibrosis stage and liver fat reduction were observed. Also produced substantial weight loss of up to 18.7%. GI side effects were most common.

  strong

Stacks featuring this peptide

Research Summary

## Tier 1 — Human Clinical Trials - Phase II (BI 456906-0002): 387 patients with overweight/obesity, 46 weeks, up to 18.7% body weight reduction at highest dose - Phase IIb MASH trial: significant histological improvement, 47-62% MASH resolution rate, with dose-dependent liver fat reductions >50% - Phase III SYNCHRONIZE program: ongoing for obesity and MASH indications (multiple trials registered on ClinicalTrials.gov) - Safety: GI adverse events (nausea 20-40%, diarrhea 15-20%, vomiting 10-15%) were primary tolerability concerns, mostly mild-moderate and transient - No pancreatitis signal above background rates; no thyroid C-cell concerns identified in Phase II ## Tier 2 — Mechanistic Human Data - Glucagon receptor activation confirmed by increases in amino acid catabolism markers (urea cycle intermediates) and fibroblast growth factor 21 (FGF21) - Energy expenditure increases measured by indirect calorimetry: ~80 kcal/day increase vs. placebo - Hepatic MRI-PDFF showed dose-linear fat reduction, confirming direct hepatic mechanism - Lean mass DXA data suggest proportionally less lean mass loss compared to pure GLP-1 agonists ## Tier 3 — Preclinical/Mechanistic - Rodent studies confirm dual receptor engagement with distinct signaling signatures - Glucagon receptor agonism upregulates CPT1a (fatty acid transport into mitochondria), HMGCS2 (ketogenesis), and PCK1 (gluconeogenesis) - In vitro hepatocyte models show synergistic lipid clearance with combined GLP-1/glucagon receptor activation vs. either alone ## Evidence Gaps - No long-term (>2 year) safety data - Cardiovascular outcomes trial not completed - Optimal dose for MASH vs. obesity may differ — unclear if one dose fits both - Head-to-head vs. semaglutide or tirzepatide not yet published